September 19, 2024
Ad Scientiam is proud to announce its collaboration with Abata Therapeutics on the first-ever clinical trial of ABA-101, an innovative therapy for progressive multiple sclerosis.
Through MSCopilot®, we will provide digital biomarkers that offer valuable support to this groundbreaking study.
We announce the enrollment of the First Patient In in the HARMONY 360 study, conducted in collaboration with Merck KGaA, Darmstadt, Germany, to explore multimodal remote digital monitoring of generalized Myasthenia Gravis with MyoSense 360.
October 8, 2026
At the 12th Congress of the European Academy of Neurology in Geneva, we present the first encouraging 1-year results from our MS-DETECT and MS-FLOWER studies, confirming the reliability of MSCopilot® for long-term monitoring of multiple sclerosis.
June 29, 2026
We announce a decisive step in our international development: the opening of our American subsidiary and the registration of MSCopilot® with the FDA.
April 16, 2026
Talk to our experts and discover how our solutions integrate into your practice or studies.
This site uses analytics cookies
We use Countly to measure audience and improve your experience. This data remains anonymous and is not shared with third parties.